Pharma Phorum
DECEMBER 12, 2022
There was also new data from the monarchE trial of Eli Lilly’s CDK 4/6 inhibitor Verzenio (abemaciclib) in combination with endocrine therapy as an adjuvant treatment for patients with high risk, early-stage HR+/HER2- breast cancer.
XTalks
OCTOBER 18, 2022
Disruption is very commonly witnessed in the life sciences industry hence human resources (HR) departments need to continuously come up with new talent strategies and recruitment practices to stay progressive. . What exactly does the future of HR look like as digital transformation escalates?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 6, 2022
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy. The study enrolled 222 patients with aggressive forms of HR+/HER2− MBC (i.e., months (HR=0.54; 95% CI: 0.36-0.79; p=.0007)
The Pharma Data
SEPTEMBER 8, 2022
months; hazard rate( HR) = 0.79;( 95 confidence interval( CI)0.65-0.96); p = 0.02). Trodelvy has not been approved by any nonsupervisory agency for the treatment of HR/ HER2- metastatic bone cancer. About HR/ HER2- bone Cancer. – 3.2
Pharma Mirror
FEBRUARY 28, 2021
The post Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval appeared first on Pharma Mirror Magazine. Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an ?-specific
The Pharma Data
OCTOBER 27, 2022
roughly 70 of bone cancer tumours are considered HR-positive and HER2-low or negative.2 Endocrine curatives are extensively used for the treatment of HR-positive bone cancer, but numerous cases with advanced complaint develop resistance to 1st- line CDK4/ 6 impediments and estrogen receptor- targeting curatives, emphasizing the need for fresh options.3 Capivasertib plus Faslodex significantly bettered progression-free survivalvs.
BioTech 365
JUNE 21, 2022
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast … Continue reading → Business Wire
The Pharma Data
MARCH 3, 2023
Food and Drug Administration (FDA) approved an expanded indication for Verzenio ® (abemaciclib), in combination with endocrine therapy (ET), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at a high risk of recurrence. The addition of Verzenio to ET reduced the risk of recurrence by 35% compared to ET alone (HR=0.653 [95% CI: 0.567-0.753]).
BioTech 365
SEPTEMBER 28, 2021
Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “HR+/HER2-VE Breast Cancer – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This HR+/HER2-VE Breast … Continue reading → Business Wire
BioTech 365
NOVEMBER 16, 2020
Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services CALGARY, Alberta–(BUSINESS WIRE)–#albertadentist–With businesses everywhere struggling to keep their doors … Continue reading → Business Wire
The Pharma Data
MARCH 7, 2022
Nasdaq: GILD) today announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy ® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy.
BioTech 365
SEPTEMBER 5, 2020
| Añadir a lista de seguimiento Biotech365 : ^^BIORAD 7500502 Signal Importación Módulo Hr – Nuevo BioMarketplace You want to propose your products or a Biotech … Continue reading → #BioMarketplace #BioMarketplace_ES #Biorad71,11 EURFecha de finalización: miércoles sep-16-2020 8:31:12 CESTCómpralo ya por sólo: 71,11 EUR¡Cómpralo ya! |
BioSpace
MAY 5, 2021
We interviewed Krissy Fuller, a human resources consultant, to learn more about the issue of mandated vaccines from an HR perspective and shared her predictions on what changes she thinks will last after the pandemic
BioTech 365
SEPTEMBER 3, 2021
Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R. 3 Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R.
XTalks
JULY 31, 2020
HR organizations rely on access to employee data to address regulatory requirements, support modernization projects, manage talent, and address mergers and acquisitions. Why is having the right HR technology so important?
The Pharma Data
SEPTEMBER 21, 2020
New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in patients whose tumours are PIK3CA positive.
Scienmag
DECEMBER 9, 2021
Credit: SWOG/The Hope Foundation In an analysis of data from postmenopausal patients with hormone receptor-positive breast cancer, a standard measure of gene expression known as the sensitivity-to-endocrine-therapy (SET2,3) index was found to have prognostic value that complemented the known prognostic value of the 21-gene breast recurrence score.
The Pharma Data
MARCH 25, 2021
months with letrozole alone (HR 0.58: 95% CI, 0.49 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53 This real-world cohort includes more than 1,400 women with HR+, HER2- mBC with any extent of visceral disease.
BioTech 365
SEPTEMBER 19, 2021
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer With the MONALEESA-2 final analysis, only … Continue reading → GlobeNewswire
BioTech 365
APRIL 15, 2021
BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada OTTAWA, Ontario–(BUSINESS … Continue reading → Business Wire
BioTech 365
DECEMBER 10, 2021
Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i New data underscore efficacy … Continue reading → GlobeNewswire
XTalks
SEPTEMBER 29, 2021
Xtalks spoke with two HR professionals to find out how companies are handling the transition from a work-from-home policy to a hybrid or back-to-work model. News Blogs Career Insights Blogs Featured Pandemic Highlight COVID-19 Life Science Jobs HR
Scienmag
SEPTEMBER 20, 2020
Data from latest research presented at the ESMO Virtual Congress 2020 Lugano, Switzerland, 20 September 2020 – Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study […].
BioTech 365
MARCH 26, 2021
Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Results from pre-planned subgroup … Continue reading → GlobeNewswire
BioTech 365
DECEMBER 9, 2020
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast … Continue reading → Business Wire
XTalks
FEBRUARY 17, 2021
Therefore, the role of HR is critical at any organization. And on February 19, join An Insider’s Look: How Syneos Health is Shortening the Distance from Lab to Life in Clinical Trials for key industry HR insights for jobseekers. This includes hiring practices and HR management.
BioTech 365
SEPTEMBER 19, 2020
In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone1 14+ months OS improvement was achieved in … Continue reading → GlobeNewswire
Pharmaceutical Technology
FEBRUARY 5, 2023
Trodelvy has been approved for HR+/HER2- breast cancer adult patients who have previously received endocrine-based therapy and a minimum of two additional systemic therapies in the metastatic setting.
Pharmaceutical Technology
JANUARY 13, 2023
The regulatory approval was based on the data obtained from the DESTINY-Breast04 Phase III trial, which was conducted in HR-positive or HR-negative, HER2-low unresectable or metastatic breast cancer patients, who have received one or two prior lines of chemotherapy.
Scienmag
JUNE 30, 2021
Credit: NTU Singapore Nanyang Technological University, Singapore (NTU Singapore) is collaborating with the Institute for Human Resource Professionals (IHRP) to launch two new MiniMasters™ programmes to develop talent in human resources (HR).
Pharmaceutical Technology
JANUARY 27, 2023
The European Union (EU) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (trastuzumab deruxtecan) as monotherapy to treat unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer adult patients.
Pharmaceutical Technology
MARCH 6, 2023
Verzenio along with endocrine therapy (ET) has received approval as an adjuvant treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) adult patients who are at a high recurrence risk.
BioSpace
JUNE 5, 2022
Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology's annual meeting
The Pharma Data
OCTOBER 27, 2022
roughly 70 of bone cancer tumours are considered HR-positive and HER2-low or negative.2 In addition to these results, the Company has also blazoned moment positive results from the CAPitello- 291 Phase III trial of capivasertib in HR-positive advanced bone cancer.
Pharmaceutical Technology
SEPTEMBER 13, 2022
Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide.
Pharmaceutical Technology
JULY 8, 2022
The company claimed that the utmost benefit is reported in hormone-receptor positive (HR+) women and those who commence treatment with Nerlynx within a year of receiving trastuzumab-based therapy.
Pharma Mirror
OCTOBER 17, 2022
International biopharma executive Guillaume Herry has been appointed as CEO, while HR executive Joanne Reichardt has been appointed Head of People & Culture.
Pharmaceutical Technology
AUGUST 8, 2022
According to the trial data, Enhertu lowered disease progression or mortality risk by 50% compared with chemotherapy according to the physician’s choice in HER2-low metastatic breast cancer patients with hormone receptor (HR)-positive disease or HR-negative disease.
Pharmaceutical Technology
JULY 1, 2022
The latest filing is based on non-clinical and clinical data for Paxlovid and also comprised data from the Phase II/III EPIC-HR clinical trial.
The Pharma Data
NOVEMBER 22, 2022
The Verzenio oral and bill donations will give streamlined clinical data from ongoing studies in early and advanced forms of hormone receptor-positive( HR), mortal epidermal growth factor receptor 2-negative( HER2-) bone cancer. An oral donation will give results from apre-planned overall survival( zilches) analysis from the Phase 3 monarchE study in HR, HER2-, knot-positive, high threat early bone cancer, including four- time efficacity issues.
The Pharma Data
AUGUST 29, 2022
– Late-Breaking Presentation of Phase 3 TROPiCS-02 Study of Trodelvy ® Demonstrates Overall Survival Benefit in Pre-Treated HR+/HER2- Metastatic Breast Cancer –. About HR/ HER2- bone Cancer.
Expert insights. Personalized for you.
105 
Let's personalize your content